9th DIA China Annual Meeting

May 21-24 | Shanghai International Convention Center

Drug Innovation Driven by Unmet Medical Needs

QUICK GUIDE:

DIA

Weibo | Wechat Subscription | DIA China Home Page

SUNDAY, MAY 21, 2017 | PRE-CONFERENCE WORKSHOPS

	Workshop 1	Workshop 2	Workshop 3 / Workshop 5	Workshop 4
8:30 - 12:00	5th Floor, 5D+E Transformation of Generic Drug Enterprise under New Policy and Regulatory Environment		5th Floor, 5F Statistics for Medical Affairs	5th Floor, 5B+C Data Process Review
13:30 - 17:00		5th Floor, 5F Risk Management in Clinical Trial: From Protecting Safety, Right, and Welfare of Study Subjects to Ensuring Safety Data Integrity	5th Floor Yangtze River Hall CFDA/DIA Joint Workshop on ICH	

MONDAY, MAY 22, 2017 | CONFERENCE DAY 1

13:30 - 17:30	Opening Plenary Session + Special Forum | 7th Floor, Grand Ballroom I (Refreshment Break | 15:00 - 15:30)
17:00 - 19:00	Welcome Reception 1st Floor

TUESDAY, MAY 23, 2017 | CONFERENCE DAY 2

	Theme 1	Theme 2 / Theme 3	Theme 4
	Regulatory Science	Theme 2: CFDA Townhall Theme 3: Multi-collaborations – A Pathway to High Quality Studies	Oncology Drug Development
8:30 - 10:00	Session 0101 3rd Floor, Yellow River Hall Worldwide Regulatory Science Emerging Focus	Session 0301 7th Floor, Pearl Hall Progress and Impact of New Regulations on Clinical Research	Session 0401 5th Floor, 5B+C; 5J Live Satellite Target Discovery & Preclincal Development
10:00 - 10:30	Refreshment Break 1st Floor		
10:30 - 12:00	Session 0102 3rd Floor, Yellow River Hall Consideration and Discussion of Implementing ICH Guideline in China	Session 0302 7th Floor, Pearl Hall Improving Clinical Study Quality via Multi-Collaborations	Session 0402 5th Floor, 5B+C; 5J Live Satellite Early Stage Clinical Development
12:00 - 13:30	Luncheon		
13:30 - 15:00	China Food and Drug Administration (CFDA) Town Hall - Part I | 3rd Floor, Auditorium (Main Session); Yellow River Hall (Live Satellite)		
15:00 - 15:30	Refreshment Break 1st Floor		
15:30 - 17:00	China Food and Drug Administration (CFDA) Town Hall - Part II | 3rd Floor, Auditorium (Main Session); Yellow River Hall (Live Satellite)		

WEDNESDAY, MAY 24, 2017 | CONFERENCE DAY 3

	Theme 1	Theme 3	Theme 4
	Regulatory Science	Multi-collaborations – A Pathway to High Quality Studies	Oncology Drug Development
8:30 - 10:00	Session 0105 3rd Floor, Yellow River Hall Regulatory Science and Review Quality: Learning Good Practice from the Other Competent Regulatory Bodies	Session 0305 7th Floor, Pearl Hall High Quality of Clinical Research Comes from Risk-Management Driven Project Management System	Session 0405 5th Floor, 5B+C; 5J Live Satellite Late Stage Clinical Development
10:00 - 10:30	Refreshment Break 1st Floor		
10:30 - 12:00	Session 0106 3rd Floor, Yellow River Hall Consideration and Case Study of Expediting Development and Review of New Drugs	Session 0306 7th Floor, Pearl Hall Responsibilities and Management of Stakeholders in Clinical Research	Session 0406 5th Floor, 5B+C; 5J Live Satellite Immuno Oncology
12:00 - 13:30	Luncheon		
13:30 - 15:00	Session 0107 3rd Floor, Yellow River Hall Products Regulatory Supervision and Quality Control	Session 0307 7th Floor, Pearl Hall How to Ensure the Data Integrity in Clinical Trials	Session 0407 5th Floor, 5B+C; 5J Live Satellite Precision Medicine & In-Vitro Diagnosis
15:00 - 15:30	Refreshment Break 1st Floor		
15:30 - 17:00	Session 0108 3rd Floor, Yellow River Hall To Accelerate Regulatory Approval of and Patient's Access to Safe, Effective and Quality Medicine —— The Role of Good Review and Submission Practice	Session 0308 7th Floor, Pearl Hall Apply New Technology/Method to Improve Data Quality in Clinical Trial	Session 0408 5th Floor, 5B+C; 5J Live Satellite Regulatory & World-Wide Development

TUESDAY, MAY 23, 2017 | CONFERENCE DAY 2

	Theme 5	Theme 6	Theme 7	Theme 8
	Quantitative Science in Transformation	Focus on Medical Value to Satisfy Unmet Patient Needs	Biologics & Biosimilar	Patient Safety – A Constant Focus
8:30 - 10:00	Session 0501 3rd Floor, 3C+D Quantitative Science and New Regulatory Guidance	Session 0601 3rd Floor, 3I+J The Evolvement of Medical Affairs in New Era	Session 0701 5th Floor, Yangtze River Hall Clinical Trial Design of Biosimilar Part I	Session 0801 5th Floor, 5D+E Current Development in Pharmacovigilance – The Importance to Know What's Going on
10:00 - 10:30	Refreshment Break 1st Floor			
10:30 - 12:00	Session 0502 3rd Floor, 3C+D CDISC/EDC Guidelines and Implementation	Session 0602 3rd Floor, 3I+J Real-World Evidence and Health-Outcome	Session 0702 5th Floor, Yangtze River Hall Clinical Trial Design of Biosimilar Part II	Session 0802 5th Floor, 5D+E Established Products/Injectable Products Safety Monitoring and Risk Management
12:00 - 13:30	Luncheon			
13:30 - 15:00	China Food and Drug Administration (CFDA) Town Hall - Part I | 3rd Floor, Auditorium (Main Session); Yellow River Hall (Live Satellite)			
15:00 - 15:30	Refreshment Break 1st Floor			
15:30 - 17:00	China Food and Drug Administration (CFDA) Town Hall - Part II | 3rd Floor, Auditorium (Main Session); Yellow River Hall (Live Satellite)			

WEDNESDAY, MAY 24, 2017 | CONFERENCE DAY 3

	Theme 5	Theme 6	Theme 7	Theme 8 / Theme 6-2
	Quantitative Science in Transformation	Focus on Medical Value to Satisfy Unmet Patient Needs	Biologics & Biosimilar	Theme 8 Patient Safety - A Constant Focus Theme 6-2 : Clinical Submission Documents - Embrace New Regulatory Requirements
8:30 - 10:00	Session 0505 3rd Floor, 3C+D Utilization of Real World Data for Drug Development and Drug Evaluation	Session 0605 3rd Floor, 3I+J Multi-Channels Medical Communication	Session 0705 5th Floor, Yangtze River Hall Recent Trends in the Regulation of Biopharmaceutical Products	Session 0805 5th Floor, 5D+E How to Improve Safety Communication-Perspectives from Health Authority, Hospital and Industry
10:00 - 10:30	Refreshment Break 1st Floor			
10:30 - 12:00	Session 0506 3rd Floor, 3C+D Accelerate Drug Development with Innovative Statistical Method	Session 0606 3rd Floor, 3I+J "Medical Driven" in Cross Functions' Eyes	Session 0706 5th Floor, Yangtze River Hall Regulating Biologics under MAH Pilot Program	Session 0806 5th Floor, 5D+E Safety in Oncological Treatment
12:00 - 13:30	Luncheon			
13:30 - 15:00	Session 0507 3rd Floor, 3C+D Statistical Considerations in Clinical Development	Session 0607 3rd Floor, 3I+J The Role of Medical Affairs in Product Life Cycle Management	Session 0707 5th Floor, Yangtze River Hall Pharmacometrics in Early Stage of Clinical Development	Session 0607-2 5th Floor, 5D+E Development of Clinical Documents for Regulatory Submission to Meet the CFDA Requirements and to Proactively Address Potential Inspection Points
15:00 - 15:30	Refreshment Break 1st Floor			
15:30 - 17:00	Session 0508 3rd Floor, 3C+D New Ideas and Emerging Trends in Statistical Methods for Multi-Regional Clinical Trials	Session 0608 3rd Floor, 3I+J Career Development of Medical Affairs Personnel: Face to Face with the Senior Leaders	Session 0708 5th Floor, Yangtze River Hall Development of Cell Therapy and Regulatory Considerations	Session 0608-2 5th Floor, 5D+E (English Only) Cross-Functional Collaboration to Prepare High Quality Clinical Documents to Support IND, Pre-NDA And NDA Submissions

TUESDAY, MAY 23, 2017 | CONFERENCE DAY 2

	Theme 9	Theme 10	Theme 11	Theme 13
	The Strategy and Implementation of Early Clinical Development for Innovative Drugs	China-Anchored Drug Development and Entrepreneurship Forum	Hot Topics & Late Breaker	White Paper Showcase
8:30 - 10:00	Session 0901 5th Floor, 5F Strategy of Clinical Development	Session 1001 3rd Floor, 3E New Drug Development by China Domestics R&D Company	Session 1101 3rd Floor, 3G Big Data and Artificial Intelligence in Clinical Research and Patient Recruitment	Session 1301 5th Floor, 5H Sinyoo Information Technology White Paper Showcase New Model for Real World Data
10:00 - 10:30	Refreshment Break 1st Floor			
10:30 - 12:00	Session 0902 5th Floor, 5F Risk Mitigation in Early Drug Development	Session 1002 3rd Floor, 3E Chinese R&D Company Going to Overseas		Session 1302 5th Floor, 5H Covance White Paper Showcase Optimizing Clinical Trials with Protocol Innovation and Speedy Patient Recruitment
12:00 - 13:30	Luncheon			
13:30 - 15:00	China Food and Drug Administration (CFDA) Town Hall - Part I | 3rd Floor, Auditorium (Main Session); Yellow River Hall (Live Satellite)			
15:00 - 15:30	Refreshment Break 1st Floor			
15:30 - 17:00	China Food and Drug Administration (CFDA) Town Hall - Part II | 3rd Floor, Auditorium (Main Session); Yellow River Hall (Live Satellite)			

WEDNESDAY, MAY 24, 2017 | CONFERENCE DAY 3

	Theme 9	Theme 10	Theme 11 / Theme 12	Theme 13
	The Strategy and Implementation of Early Clinical Development for Innovative Drugs	China-Anchored Drug Development and Entrepreneurship Forum	Theme 5: Quantitative Science in Transformation Theme 11: Hot Topics & Late Breaker Theme 12: Rare Disease: Unsatisfied Market Demand	White Paper Showcase
8:30 - 10:00	Session 0905 5th Floor, 5F How to Improve Development Efficiency and Save Clinical Resource	Session 1005 3rd Floor, 3E (English Only) International Policy or Practices for Chinese Company	Session 0505-2 3rd Floor, 3G Clinical Data - Regulatory Requirement	Session 1305 5th Floor, 5H Beijing Jingwei Chuanqi Medicine White Paper Showcase Clinical Trial Quality & Risk Management
10:00 - 10:30	Beijing Jingwei Chuanqi Medicine White Paper Showcase Refreshment Break 1st Floor			
10:30 - 12:00	Session 0906 5th Floor, 5F Panel Discussion: The Strategy and Implementation of Early Clinical Development for Innovative Drugs	Session 1006 3rd Floor, 3E Licensing and Partnership in R&D	Session 1106 3rd Floor, 3G Late Breaker: Panel Discussion on New Policy Changes of Imported Product Registration	Session 1306 5th Floor, 5H MobileMD System White Paper Showcase Uncover the New Perspective of Clinical Trial Management with Innovative Clinical Trial Platform
12:00 - 13:30	Luncheon			
13:30 - 15:00		Session 1007 3rd Floor, 3E Start-up in Drug Development	Session 1207 3rd Floor, 3G Rare Disease: Unsatisfied Market Demand - Part I	Session 1307 5th Floor, 5H DXC White Paper Showcase eCTD Dossier Publishing & CDISC Compliance
15:00 - 15:30	Refreshment Break 1st Floor			
15:30 - 17:00			Session 1208 3rd Floor, 3G Rare Disease: Unsatisfied Market Demand - Part II	